All In Biotech

Drug Trial Radar · NCT00159744

3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)

A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs. Olanzapine and Placebo in In-Patients With an Acute Manic Episode Clinical Trial Protocol 7501004 (Secondary Title: ARES)

Last checked: Nov 20, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 488 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

488

Actual

Start

Nov 30, 2004

Primary completion

Apr 29, 2006

Study completion Apr 29, 2006

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
Collaborators
Pfizer
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bipolar disorder is characterized by mood swings that range from high (manic) to low (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed episodes). Asenapine is an investigational medication for the treatment of manic or mixed episodes of bipolar disorder. This is a 3-week study that will test the safety and efficacy of this medication. Patients will receive either asenapine, olanzapine (a medication that is already approved for the treatment of bipolar mania), or placebo (no active medication). Patients will be required to stay in the hospital for at least the first seven days of treatment. Patients that complete the 3 week study may be eligible to continue in extension studies for an additional 9 (study A7501006) to 49 (study A7501007) weeks.

Conditions

  • Bipolar Disorder

Interventions

  • AsenapineDrug

    Asenapine, 3 weeks

  • OlanzapineDrug

    Olanzapine, 3 weeks

  • PlaceboDrug

    placebo, 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale)Time frame: The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.